No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305

por Kapadia, Shashi N., Wu, Chunyuan, Mayer, Kenneth H., Wilkin, Timothy J., Amico, K. Rivet, Landovitz, Raphael J., Andrade, Adriana, Chen, Ying Q., Chege, Wairimu, McCauley, Marybeth, Gulick, Roy M., Schackman, Bruce R.
Publicado 2018

Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077

por Tolley, Elizabeth E., Zangeneh, Sahar Z., Chau, Gordon, Eron, Joe, Grinsztejn, Beatriz, Humphries, Hilton, Liu, Albert, Siegel, Marc, Bertha, Maseko, Panchia, Ravindre, Li, Sue, Cottle, Leslie, Rinehart, Alex, Margolis, David, Jennings, Andrea, McCauley, Marybeth, Landovitz, Raphael J.
Publicado 2020

Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions

por Amico, K Rivet, Ramirez, Catalina, Caplan, Margaret R, Montgomery, Brooke EE, Stewart, Jennifer, Hodder, Sally, Swaminathan, Shobha, Wang, Jing, Darden‐Tabb, Noshima Y, McCauley, Marybeth, Mayer, Kenneth H, Wilkin, Timothy, Landovitz, Raphael J, Gulick, Roy, Adimora, Adaora A
Publicado 2019

Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study

por Seneviratne, Herana Kamal, Hamlin, Allyson N., Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y., Kuo, Irene, Hosseinipour, Mina C., Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Adeyeye, Adeola, Rinehart, Alex R., McCauley, Marybeth, Eron, Joseph S., Cohen, Myron S., Landovitz, Raphael J., Hendrix, Craig W., Bumpus, Namandjé N.
Publicado 2021

Correction to “Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study”

por Seneviratne, Herana Kamal, Hamlin, Allyson N., Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y., Kuo, Irene, Hosseinipour, Mina C., Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Adeyeye, Adeola, Rinehart, Alex R., McCauley, Marybeth, Eron, Joseph J., Cohen, Myron S., Landovitz, Raphael J., Hendrix, Craig W., Bumpus, Namandjé N.
Publicado 2021

Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052

por Palumbo, Philip J., Wilson, Ethan A., Piwowar-Manning, Estelle, McCauley, Marybeth, Gamble, Theresa, Kumwenda, Newton, Makhema, Joseph, Kumarasamy, Nagalingeswaran, Chariyalertsak, Suwat, Hakim, James G., Hosseinipour, Mina C., Melo, Marineide G., Godbole, Sheela V., Pilotto, Jose H., Grinsztejn, Beatriz, Panchia, Ravindre, Chen, Ying Q., Cohen, Myron S., Eshleman, Susan H., Fogel, Jessica M.
Publicado 2017

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

por Landovitz, Raphael J., Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y., Magnus, Manya, Hosseinipour, Mina C., Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Richardson, Paul, Marzinke, Mark A., Hendrix, Craig W., Eshleman, Susan H., Zhang, Yinfeng, Tolley, Elizabeth, Sugarman, Jeremy, Kofron, Ryan, Adeyeye, Adeola, Burns, David, Rinehart, Alex R., Margolis, David, Spreen, William R., Cohen, Myron S., McCauley, Marybeth, Eron, Joseph J.
Publicado 2018

Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

por Marzinke, Mark A., Fogel, Jessica M., Wang, Zhe, Piwowar-Manning, Estelle, Kofron, Ryan, Moser, Amber, Bhandari, Pradip, Gollings, Ryann, Bushman, Lane R., Weng, Lei, Halvas, Elias K., Mellors, John, Anderson, Peter L., Persaud, Deborah, Hendrix, Craig W., McCauley, Marybeth, Rinehart, Alex R., St Clair, Marty, Ford, Susan L., Rooney, James F., Adeyeye, Adeola, Chariyalertsak, Suwat, Mayer, Kenneth, Arduino, Roberto C., Cohen, Myron S., Grinsztejn, Beatriz, Hanscom, Brett, Landovitz, Raphael J., Eshleman, Susan H.
Publicado 2023